FDA Wants Solzira Restless Legs Data Reformatted
This article was originally published in The Pink Sheet Daily
Executive Summary
Filing’s content is unaffected, says GlaxoSmithKline, which withdrew the recently submitted NDA but will resubmit it “as quickly as possible.”